Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC41 in Adults With NASH
NCT05118360Phase 2Withdrawn
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of ASC-41 in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Gannex Pharma Co., Ltd. Primary endpoint: Percent of subjects with histological reduction in NAS ≥2 points at 52 weeks. Planned start Dec 2023; status: withdrawn.
02
Drugs
ASC-41
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05118360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05118360.